Literature DB >> 26709735

Trends in respiratory syncytial virus bronchiolitis hospitalizations in children less than 1 year: 2004-2012.

Manuel Sanchez-Luna1, Francisco J Elola2, Cristina Fernandez-Perez2, Jose L Bernal3, Adriana Lopez-Pineda2.   

Abstract

OBJECTIVE: To analyze trends in health outcomes and the influence of risk factors in children under 1 year with acute bronchiolitis due to respiratory syncytial virus (RSV bronchiolitis). A risk-adjustment model for RSV bronchiolitis in-hospital mortality was also developed. RESEARCH DESIGN AND METHODS: Retrospective study of hospitalizations for RSV bronchiolitis in children aged <1 year from 2004 to 2012. We used nationally representative data from the Spanish National Health Service records.
RESULTS: Over the study period, the annual hospital discharges for RSV bronchiolitis ranged between 6390 and 8637. The annual in-hospital mortality rate ranged from 120 (2004) to 69 (2012) per 100,000 hospitalizations and the mean length of stay decreased steadily from 6.5 to 5.2 days (p < 0.001); 98.3% of hospitalizations for RSV bronchiolitis were children without risk factors. The in-hospital mortality rate due to RSV bronchiolitis in children with risk factors was 18.8 times higher than non-high-risk children and, in adjusted analyses, the OR of in-hospital mortality due to RSV bronchiolitis was higher than that due to other causes. LIMITATIONS: This study is a retrospective analysis, based on administrative data. It does not include data about pre- or in-hospital treatments, and has the limitations inherent in procedures for determining risk-adjusted mortality rates. Socioeconomic and environmental factors have not been considered in this study.
CONCLUSIONS: RSV bronchiolitis is a leading cause of hospitalizations for infants under 1 year and has not shown incidence reduction over a 9 year period. Risk factors increase the in-hospital mortality risk and it is higher if the hospitalization cause is RSV bronchiolitis than any other reason.

Entities:  

Keywords:  Bronchiolitis; In-hospital mortality; Readmission; Respiratory syncytial virus

Mesh:

Year:  2016        PMID: 26709735     DOI: 10.1185/03007995.2015.1136606

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  13 in total

1.  Parental Perspectives on Continuous Pulse Oximetry Use in Bronchiolitis Hospitalizations.

Authors:  Kevin W Chi; Eric R Coon; Lauren Destino; Alan R Schroeder
Journal:  Pediatrics       Date:  2020-07-16       Impact factor: 7.124

2.  Safety and effectiveness of bubble continuous positive airway pressure as respiratory support for bronchiolitis in a pediatric ward.

Authors:  Marta Agüera; Maria Melé-Casas; Maria Mercedes Molina; Martí Pons-Odena; Mariona F de-Sevilla; Juan-José García-García; Cristian Launes; Laura Monfort
Journal:  Eur J Pediatr       Date:  2022-09-21       Impact factor: 3.860

3.  Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection.

Authors:  Cristina Capella; Supranee Chaiwatpongsakorn; Erin Gorrell; Zachary A Risch; Fang Ye; Sara E Mertz; Sara M Johnson; Melissa Moore-Clingenpeel; Octavio Ramilo; Asuncion Mejias; Mark E Peeples
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

4.  Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.

Authors:  M Sanchez-Luna; R Burgos-Pol; I Oyagüez; J Figueras-Aloy; M Sánchez-Solís; F Martinón-Torres; X Carbonell-Estrany
Journal:  BMC Infect Dis       Date:  2017-10-17       Impact factor: 3.090

5.  Respiratory syncytial virus hospitalization in children in northern Spain.

Authors:  Natividad Viguria; Iván Martínez-Baz; Laura Moreno-Galarraga; Luis Sierrasesúmaga; Blanca Salcedo; Jesús Castilla
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

6.  Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.

Authors:  Renato Cutrera; Andrea Wolfler; Simonetta Picone; Giovanni A Rossi; Giuliana Gualberti; Rocco Merolla; Antonio Del Vecchio; Alberto Villani; Fabio Midulla; Andrea Dotta
Journal:  Ital J Pediatr       Date:  2019-11-09       Impact factor: 2.638

7.  TEMPORAL TREND OF HOSPITALIZATIONS FOR ACUTE BRONCHIOLITIS IN INFANTS UNDER ONE YEAR OF AGE IN BRAZIL BETWEEN 2008 AND 2015.

Authors:  Kanama Tumba; Talitha Comaru; Camila Machado; Manoel Ribeiro; Leonardo Araújo Pinto
Journal:  Rev Paul Pediatr       Date:  2019-11-25

8.  Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.

Authors:  Ralph Schmidt; Istvan Majer; Natalia García Román; Alejandra Rivas Basterra; ElizaBeth Grubb; Constancio Medrano López
Journal:  Health Econ Rev       Date:  2017-12-19

9.  Human respiratory syncytial virus and hospitalization in young children in Italy.

Authors:  Parvanè Kuhdari; Federica Brosio; Cristina Malaventura; Armando Stefanati; Andrea Orsi; Giancarlo Icardi; Giovanni Gabutti
Journal:  Ital J Pediatr       Date:  2018-05-04       Impact factor: 2.638

10.  Risk factors of severe hospitalized respiratory syncytial virus infection in tertiary care center in Thailand.

Authors:  Puneyavee Aikphaibul; Tuangtip Theerawit; Jiratchaya Sophonphan; Noppadol Wacharachaisurapol; Nattapong Jitrungruengnij; Thanyawee Puthanakit
Journal:  Influenza Other Respir Viruses       Date:  2020-08-12       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.